News

Article

FDA Converts Eisai Alzheimer’s Treatment to Traditional Approval

Author(s):

Eisai’s lecanemab-irmb was converted from an accelerated approval to a traditional approval.

FDA announced on July 6, 2023, that it had converted its approval of Eisai’s Leqembi (lecanemab-irmb), indicated to treat patients with Alzheimer's Disease, from an accelerated approval to a traditional approval. Originally granted approval in January, the conversion followed a confirmatory trial which FDA determined verified clinical benefit. Lecanemab-irmb is an amyloid beta-directed therapy that is designed to reduce amyloid plaques that form in the brain, which is a defining pathophysiological feature of Alzheimer’s Disease.

The confirmatory study, Study 301, was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that enrolled 1,795 Alzheimer’s patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid beta pathology. According to the release, lecanemab-irmb demonstrated a statistically significant and clinically meaningful reduction of decline from baseline to 18 months on the primary endpoint, the Clinical Dementia Rating Scale Sum of Boxes score, relative to placebo. Statistically significant differences between treatment groups were also demonstrated on all secondary endpoints.

“Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease,” said Teresa Buracchio, acting director, Office of Neuroscience, Center for Drug Evaluation and Research, FDA, in the release. “This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease.”

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content